Sugi Predict

Sugi Predict / Compounds / SCHEMBL718625

SCHEMBL718625

SCHEMBL718625

O=[N+]([O-])c1ccccc1NC1CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 5/20 0.65
▸ HCAR3 P49019 3/20 0.58
▸ MAPT P10636 5/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ CASP7 P55210 1/20 0.53
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ GAA P10253 3/20 0.51
▸ GLA P06280 1/20 0.51
▸ CYP1A2 P05177 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ PKM P14618 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KAT2B Q92831 1/20 0.46
▸ WNK1 Q9H4A3 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2930805 0.93 MAPK1 (0.62) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL4077406 0.93 MAPK1 (0.62) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL30936592 0.93 MAPK1 (0.62) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL29065575 0.92 MAPK1 (0.58) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL22725465 0.92 MAPK1 (0.58) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL8724028 0.92 MAPK1 (0.61) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL30936655 0.92 MAPK1 (0.58) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL22725450 0.92 MAPK1 (0.58) MAPK1HCAR3MAPTALDH1A1L3MBTL1
SCHEMBL541921 0.91 KMT2A (0.64) MAPK1HCAR3MAPTALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL28635823 0.91 MAPK1 (0.56) MAPK1HCAR3MAPTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 — — US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 — — US disclosed
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof INVENTISBIO CO LTD (CN) 2024-06-27 — — US disclosed
CN-113896744-B Selective EGFR inhibitor 成都先导药物开发股份有限公司 2024-04-16 — — CN disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 — — EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 — — EP disclosed
US-11383220-B1 Method and material for synthesis and purification by use of a coated solid substrate Faster Chemistry LLC (US) 2022-07-12 — — US disclosed
CN-113896744-A Selective EGFR inhibitor 成都先导药物开发股份有限公司 2022-01-07 — — CN disclosed
US-11203589-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof InventisBio Co., Ltd. (CN) 2021-12-21 — — US disclosed
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SELENITY THERAPEUTICS (BERMUDA), LTD. (BM) 2021-10-21 — — US disclosed
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
US-20080207590-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-08-28 — — US disclosed
WO-2008055068-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-05-08 — — WO disclosed
WO-2008055068-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-05-08 — — WO disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 — — WO disclosed
EP-0276942-B1 6-BETA(SUBSTITUTED)-(S)-HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF PFIZER INC. (US) 1992-04-01 — — EP disclosed
US-4782050-A BACTERICIDES PFIZER INC. (US) 1988-11-01 — — US disclosed
EP-0276942-A1 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof PFIZER INC. (US) 1988-08-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208967-A1 Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof EGFR, WEE1, DPYD MAPK1 482/4885HCAR3 1903/4885MAPT 4337/4885
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 MAPK1 1060/4885HCAR3 4684/4885MAPT 2593/4885
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 MAPK1 3950/4885HCAR3 4595/4885MAPT 2472/4885
US-11203589-B2 Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof EGFR, WEE1, TP53 MAPK1 1136/4885HCAR3 1635/4885MAPT 4373/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 MAPK1 2739/4885HCAR3 4012/4885MAPT 2173/4885
US-20080207590-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC11 MAPK1 3282/4885HCAR3 1745/4885MAPT 2978/4885
US-20210322409-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPK1 3598/4885HCAR3 4591/4885MAPT 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.